Capricor Therapeutics Q2 2023 Earnings Report $9.06 -0.21 (-2.27%) As of 04/4/2025 04:00 PM Eastern Earnings HistoryForecast Capricor Therapeutics EPS ResultsActual EPS-$0.29Consensus EPS -$0.34Beat/MissBeat by +$0.05One Year Ago EPSN/ACapricor Therapeutics Revenue ResultsActual Revenue$3.92 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACapricor Therapeutics Announcement DetailsQuarterQ2 2023Date8/7/2023TimeN/AConference Call ResourcesPress ReleaseCAPR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Capricor Therapeutics Earnings HeadlinesCantor Fitzgerald Brokers Lift Earnings Estimates for CAPRApril 5 at 2:37 AM | americanbankingnews.comCapricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio DayApril 1, 2025 | markets.businessinsider.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 5, 2025 | Porter & Company (Ad)Check Out What Whales Are Doing With CAPRMarch 28, 2025 | benzinga.comCapricor Therapeutics Announces FDA Acceptance of Biologics License Application for Deramiocel in Duchenne Muscular Dystrophy CardiomyopathyMarch 21, 2025 | nasdaq.comIs Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comSee More Capricor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email. Email Address About Capricor TherapeuticsCapricor Therapeutics (NASDAQ:CAPR), Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. View Capricor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
